Xiamen Amoytop Biotech (SHA:688278) subsidiary, Bosai Gene Transcription Technology, will acquire some assets of Skyline Therapeutics for $15 million, with additional milestones and sales-based payments of up to $43 million, according to a Monday filing with the Shanghai bourse.
The deal, approved by the company's board, will make Skyline a wholly owned subsidiary.
The acquisition awaits regulatory and shareholder approvals.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。